Valneva has recently adjusted the safety label for its Chikungunya virus vaccine, Ixchiq, in response to postmarketing reports highlighting potential risks for individuals over 60 years old with multiple underlying health conditions. The updated prescribing information now includes warnings for neurologic and cardiac events, particularly among this age group.
Ixchiq is designed to safeguard individuals aged 18 and above from the Chikungunya virus, transmitted through infected Aedes mosquitoes, causing symptoms like fever, severe joint and muscle pain, headache, nausea, fatigue, and rash. The vaccine, containing a weakened form of the virus, aims to prevent manifestations akin to the disease, notably the prolonged joint pain lasting weeks to years.
Regulators emphasize that Ixchiq is most suitable for individuals facing a considerable risk of Chikungunya infection, as the chances of exposure to CHIKV are generally low for U.S. travelers. Notably, it is not recommended for those with compromised immune systems due to diseases or immunosuppressive treatments.
Following reports of severe adverse events associated with Ixchiq, including neurologic and cardiac issues in older recipients, the FDA has lifted its pause on the vaccine’s usage among the elderly. Notably, these reports have indicated 17 serious adverse events globally, with two fatalities, primarily involving individuals aged 62 to 89, with six cases reported in the United States.
European and French authorities had temporarily halted Ixchiq’s administration to assess its safety profile, later reinstating its use with the caution that it should be avoided in individuals with weakened immune systems. These decisions were influenced by adverse events following a mass vaccination campaign in response to a Chikungunya outbreak on the Island of La Réunion.
Valneva’s vaccine, initially approved for individuals over 18, is now under review for adolescent use in the U.S. Meanwhile, the European Union granted a label extension for adolescents aged 12 and above in March 2025. Valneva has also conducted phase 2 trials in children aged 1 to 11, demonstrating a robust immune response and tolerability, paving the way for a phase 3 trial slated for early 2026.
Key takeaways:
– Valneva’s Ixchiq vaccine’s safety label has been updated to include warnings for neurologic and cardiac events in individuals over 60 with multiple health conditions.
– Despite regulatory cautions, the vaccine remains a crucial preventive tool against Chikungunya virus for at-risk populations.
– Adverse events following vaccination have prompted regulatory reviews and restrictions, emphasizing the importance of risk assessment and monitoring post-vaccination.
– Ongoing trials in children and adolescents signify efforts to expand the vaccine’s utility to younger demographics, pending regulatory approvals.
Read more on managedhealthcareexecutive.com